Contineum Therapeutics, Inc. Class A Common Stock (CTNM) — Cash Flow Reinvestment Rate
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) has a Cash Flow Reinvestment Rate of 1.09x as of June 2023, reinvesting $44.49 Million (capex $31.00K plus investments $-44.46 Million) from operating cash flow of $40.67 Million. Check cash flow quality index of Contineum Therapeutics, Inc. Class A Com to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Contineum Therapeutics, Inc. Class A Common Stock Cash Flow Reinvestment Rate (2023–2023)
Historical reinvestment intensity for Contineum Therapeutics, Inc. Class A Common Stock across 1 annual periods. Explore how well can Contineum Therapeutics, Inc. Class A Com service its debt to assess how comfortably operating cash covers total debt obligations.
Annual Cash Flow Reinvestment Rate for Contineum Therapeutics, Inc. Class A Common Stock (2023–2023)
Year-by-year capital reinvestment analysis for Contineum Therapeutics, Inc. Class A Common Stock. For live market cap and broader valuation context, see Contineum Therapeutics, Inc. Class A Com market capitalisation.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2023 | 3.41x | $65.98 Million | $19.35 Million | $414.00K | — |